Core Viewpoint - The approval of the clinical trial application for M701, a bispecific antibody targeting EpCAM and CD3, marks a significant advancement in the international clinical development of a novel therapy for malignant pleural effusion (MPE), providing new hope for patients globally [1] Group 1: Product Development - The clinical trial for M701 has been approved by the U.S. Food and Drug Administration (FDA) and is set to begin on January 31, 2026 [1] - M701 specifically targets EpCAM and CD3, with EpCAM being highly expressed in tumor cells associated with malignant pleural effusion, making it a critical therapeutic target [1] - The trial is an open-label, multicenter, Phase Ib/II study aimed at evaluating the safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of M701 in patients with advanced epithelial tumors causing malignant pleural effusion [1] Group 2: Market Need - Malignant pleural effusion is a common and severe complication of malignant tumors, particularly in late-stage lung and breast cancer patients, highlighting the urgent need for innovative treatment strategies to fill clinical gaps [1] - Current treatment approaches primarily focus on palliative care, indicating a significant opportunity for new therapeutic options in this area [1]

Group 1 - The company has indicated that its 120-ton recombinant human albumin production line is expected to be completed by 2026, with new capacity dependent on equipment debugging and approval from the drug regulatory authority [2] - The company's drug, Ofumin®, is anticipated to be approved for market entry in July 2025, with steady progress in hospital access and distribution channel development [2] - There is currently a supply-demand imbalance in the market, indicating a strong demand for the company's products [2]

Core Viewpoint - The company, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a supplemental application regarding intravenous immunoglobulin, which is expected to enhance clinical safety and convenience while aligning domestic product processes with international standards [1][2]. Group 1: Product Approval and Indications - The intravenous immunoglobulin is indicated for primary immunoglobulin deficiency diseases, secondary immunoglobulin deficiency diseases, and autoimmune diseases [1]. - The product utilizes advanced purification techniques, providing significant advantages in quality and virus safety, particularly in product yield [1]. Group 2: Clinical Trials and Competitive Position - Guangdong Shuanglin has received multiple approvals for clinical trials of intravenous immunoglobulin for various indications, including primary immune thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP) [2]. - The company's diversified product development strategy is expected to enhance its competitive edge and improve the overall utilization rate of raw plasma, thereby increasing profitability [2].

Core Viewpoint - The company, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a supplemental application regarding intravenous immunoglobulin, which is expected to enhance clinical safety and convenience while aligning domestic product processes with international standards [1][2]. Group 1: Product Approval and Indications - The intravenous immunoglobulin is indicated for primary immunoglobulin deficiency diseases, secondary immunoglobulin deficiency diseases, and autoimmune diseases [1]. - The product utilizes advanced purification processes, providing significant advantages in product quality and virus safety, particularly in product yield [1]. Group 2: Clinical Trials and Competitive Position - Guangdong Shuanglin has received multiple approvals for clinical trials of intravenous immunoglobulin for various indications, including primary immune thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP) [2]. - The company's diversified product development strategy is expected to enhance its competitive capabilities and improve the overall utilization rate of raw plasma, thereby increasing profitability and core competitiveness [2].

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of the company, Guangdong Shuanglin Biological Pharmaceutical Co., Ltd., has received the acceptance notice for the supplemental application of intravenous immunoglobulin from the National Medical Products Administration, which is expected to enhance the safety and convenience of clinical medication and align domestic product processes with international standards [1] Group 1 - The application involves three specifications of intravenous immunoglobulin: 2.5g/bottle (10%, 25ml), 5g/bottle (10%, 50ml), and 10g/bottle (10%, 100ml) [1] - The main indications for the drug include primary immunoglobulin deficiency, secondary immunoglobulin deficiency diseases, and autoimmune diseases [1] - The acceptance of this application is anticipated to improve clinical medication safety and convenience [1]

图源InCephalo 瑞士生物科技公司InCephalo成立于2021年，公司致力于研发能局部作用于胶质母细胞瘤的生物制剂。该制剂基于公司专有的C-Lock技术，可提升药物在大 脑中枢神经系统中的停留时间与浓度，并在发生药物全身扩散时及时体内降解，实现对胶质母细胞瘤的安全治疗。 InCephalo由Carlo Bertozzi与Johannes vom Berg 共同创立。Carlo Bertozzi为公司首席执行官，拥有苏黎世大学生物博士学位，曾创办多家生物科技企业，并 担任Innosuisse生命科学辅导专家。Johannes vom Berg为公司首席科学官，拥有苏黎世大学博士后学位，目前担任苏黎世大学脑癌局部免疫疗法研究组组 长。 图源SwissCore InCephalo是2025年《瑞士创新100强》（TOP100 Swiss Startups）上榜企业。《瑞士创新100强》汇聚了最佳"瑞士制造"的初创及成长期科技创新 企业，是瑞士科技创新领域最具国际影响力的标杆榜单。自2011年以来，该榜单每年在瑞士全国范围内评选出100家最具开创性和市场前景的瑞 士创新企业和25家最具独角兽潜力的瑞士成长期 ...

Core Viewpoint - The company Hualan Biological (002007.SZ) has received approval from the National Medical Products Administration for clinical trials of a new drug, HL08, which is aimed at improving weight control in obese patients in addition to its original indication for type 2 diabetes management [1] Group 1 - The drug HL08 is a recombinant Exendin-4-Fc fusion protein injection [1] - The original indication for HL08 was to improve blood glucose control in patients with type 2 diabetes [1] - The newly approved indication expands its use to include weight control in obese patients [1]

Core Viewpoint - The company Hualan Biological (002007.SZ) has received approval from the National Medical Products Administration for a new drug clinical trial, expanding the indications for its drug HL08 to include weight control in obese patients in addition to its original indication for improving blood glucose control in type 2 diabetes patients [1] Group 1 - The drug HL08 is a recombinant Exendin-4-Fc fusion protein injection [1] - The original indication for HL08 was to improve blood glucose control in patients with type 2 diabetes [1] - The newly approved indication aims to assist in weight control for obese patients [1]

Core Viewpoint - The company, Hualan Biological (002007.SZ), has received approval from the National Medical Products Administration for its drug, HL08, a new generation GLP-1 receptor agonist developed in-house [1] Group 1: Drug Development - HL08 is a recombinant Exendin-4-Fc fusion protein injection [1] - The active ingredient of HL08 is a recombinant Exendin-4-Fc fusion protein, which combines Exendin-4 with the Fc fragment of IgG2 antibody [1] - The drug significantly extends the biological half-life while retaining the natural physiological functions of Exendin-4, enhancing medication convenience and therapeutic efficacy [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for a new drug, HL08, which is a recombinant Exendin-4-Fc fusion protein injection aimed at treating type 2 diabetes and obesity [1] Group 1: Drug Approval Details - The approval notification was issued on February 2, 2026, under the notification number 2026LP00310 [1] - HL08 is classified as a Class 1 therapeutic biological product and is categorized as a new drug [1] Group 2: Drug Characteristics - HL08 is a next-generation GLP-1 receptor agonist developed by the company [1] - The active ingredient is a recombinant Exendin-4-Fc fusion protein, which combines Exendin-4 with the Fc fragment of IgG2 antibody [1] - This fusion significantly extends the biological half-life of the drug, enhancing convenience and sustained efficacy in treatment [1] Group 3: Indications - The original approved indication for HL08 was to improve blood glucose control in patients with type 2 diabetes [1] - An additional indication has been approved for improving weight control in obese patients [1]